DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the Kimia Biosciences Ltd (KIMIABL) share price today?

Kimia Biosciences Ltd (KIMIABL) is trading at ₹34.33 on the BSE, up 3.16% on the day. Source: DocStoX.

What is the PE ratio of Kimia Biosciences Ltd?

Kimia Biosciences Ltd has a price-to-earnings (PE) ratio of 16.9 in the Healthcare sector.

What is the market capitalisation of Kimia Biosciences Ltd?

Kimia Biosciences Ltd has a market capitalisation of approximately ₹165 crore.

Kimia Biosciences Ltd

KIMIABL·BSE·Healthcare

₹34.33▲ +1.05 (+3.16%)

Healthcare · Pharmaceuticals & Biotechnology

High-quality returns — 54% on equity

Day₹33.44

₹34.99

52W₹23

₹7322%

Open

₹34.99

High

₹34.99

Low

₹33.44

Prev Close

₹33.28

Volume

2.0K

VWAP

₹34.52

Snapshot

Key fundamentals

Market Cap

₹165 Cr

P/E Ratio

16.91Fair

P/B Ratio

8.89

EPS

₹2.03

Book Value

₹3.75

ROE

53.70%Strong

ROCE

42.00%Efficient

Dividend Yield

0.00%

Debt / Equity

1.94High

Face Value

₹1.00

52W High

₹73.08

52W Low

₹23.20

Sector

Healthcare

Industry

Pharmaceuticals & Biotechnology

Fairly Valued

None moatHigh uncertainty

Fair value unavailable

/100

Business quality — Solid

Growth 50Profitability 68Efficiency 100Valuation 43

Plain English

Our view

High-quality returns — 54% on equity
Strong returns on equity (54%)
High leverage — debt exceeds 1.5× equity

Strengths

Strong returns on equity (54%)
Capital is working hard (ROCE 42%)
Promoters hold a controlling stake

Risks

High leverage — debt exceeds 1.5× equity

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

16.9Fair

Below 15× is value territory; above 35× prices in strong growth

ROE

53.7%Strong

Above 15% is considered healthy for Indian equities

ROCE

42.0%Efficient

Above 18% means capital is working hard

Debt/Eq

1.94High

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹165 Cr

P/B

8.89

EPS

₹2.03

Div Yield

—

What changed

Recent changes

No notable changes to report.

What matters

News impact

Overview

Valuation

Attractive

P/E 16.9×

Growth

Shrinking

-4% rev CAGR

Profitability

Excellent

53.7% ROE

Financial health

Leveraged

D/E 1.94

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover₹69,379 Cr

Trades20

VWAP₹34.52

Face value₹1.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

-3.8%

-2.9%

10Y

—

Profit

—

+11.1%

10Y

—

EPS

—

10Y

—

Profile

Pros

Company has a good return on equity (ROE) track record: 3 Years ROE 53.6%

Watch-outs

Cons

Stock is trading at 8.89 times its book value
Though the company is reporting repeated profits, it is not paying out dividend
The company has delivered a poor sales growth of -2.84% over past five years.
Tax rate seems low

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Ownership was broadly stable versus the previous quarter. The QoQ column shows each group's change versus the prior quarter.

75%

Promoter

Promoters

74.9%0.00

Public

22.9%-0.04

FII / FPI

0.0%0.00

DII

0.4%0.00

Others

1.8%

Total shareholders

12,775+24 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter74.94%

DII0.38%

Public22.88%

Others1.80%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1993, Kimia Biosciences Ltd is in the business of manufacturing and sale pharmaceutical products[1]